Prostacyclin (PGI 2 ) plays important roles in hemostasis both as a vasodilator and an endogenous inhibitor of platelet aggregation. PGI 2 functions in these roles through a specific IP receptor, a G protein-coupled receptor linked to G s and increases in cAMP. Here, we report that intracellular prostacyclin formed by expressing prostacyclin synthase in human embryonic kidney 293 cells promotes apoptosis by activating endogenous peroxisome proliferator-activated receptor ␦ (PPAR␦). In contrast, treatment of cells with extracellular prostacyclin or dibutyryl cAMP actually reduced apoptosis. On the contrary, treatment of the cells with RpcAMP (adenosine 3,5-cyclic monophosphothioate, Rp-isomer), an antagonist of cAMP, enhanced prostacyclin-mediated apoptosis. The expression of an L431A/ G434A mutant of PPAR␦ completely blocked prostacyclin-mediated PPAR␦ activation and apoptosis. These observations indicate that prostacyclin can act through endogenous PPAR␦ as a second signaling pathway that controls cell fate.